Your session is about to expire
← Back to Search
Decitabine + Filgrastim for Acute Myeloid Leukemia (MORE Trial)
MORE Trial Summary
This trial seeks to evaluate the safety and effectiveness of administering Decitabine and Filgrastim after HCT to treat children and young adults with myelodysplastic syndrome and related disorders.
MORE Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.MORE Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I agree to use birth control during the study.I have severe side effects from previous cancer treatments.I am in remission and show no minimal residual disease after a stem cell transplant.My organs are healthy enough for a stem cell transplant.I have another active cancer besides the one being studied.I am receiving a stem cell transplant from a donor.I am between 1 and 39 years old.I can take care of myself but might not be able to do heavy physical work.I do not have any unmanaged ongoing illnesses.I meet the criteria for my genetic condition to join the trial.I have chronic hepatitis B but it's under control with medication.I had hepatitis C but am now cured or have no detectable virus with treatment.My cancer is currently in remission.My leukemia has FLT3/ITD mutations.I have been diagnosed with AML, MDS, or a related blood disorder.My heart condition does not severely limit my daily activities.I am HIV-positive, on treatment, and my viral load has been undetectable for 6 months.
- Group 1: Cohort A: Standard Risk
- Group 2: Cohort B: inherited bone marrow failure (iBMF) with Increased Risk for treatment related toxicities
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has FDA approval been granted to Cohort A: Standard Risk?
"Despite the fact that Cohort A: Standard Risk is currently undergoing a Phase 2 trial, its safety has been assessed as having an intermediate rating of 2 due to preliminary data supporting this drug's security."
Can individuals younger than 25 participate in this clinical examination?
"To participate in this trial, patients must be between 1 Year and 39 Years old. It is worth noting that 859 clinical trials are currently recruiting individuals below the age of 18 while 3868 studies accept participants above 65 years old."
Could I potentially be a candidate for this trial?
"Prospective participants with acute myeloid leukemia between the ages of 1 and 39 can apply to join this clinical trial. The current enrolment cap is 37 patients."
Are there any openings for participants in this experiment currently?
"As per the clinicaltrials.gov data, this medical trial is not presently accepting participants. This research project was initially posted on April 1st 2023 and has since been amended as of March 31st 2023. Nevertheless, there are currently 4605 other trials actively recruiting patients."
Share this study with friends
Copy Link
Messenger